ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)

PRESS RELEASE

published on 08/29/2025 at 08:00, 6 months 18 days ago

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
OSE Immunotherapeutics reaffirms strategic priorities with comprehensive Q&A document ahead of AGM. Company focuses on Tedopi® and Lusvertikimab programs for value creation

Strategic Priorities OSE Immunotherapeutics Lusvertikimab Shareholder Q&A Tedopi®
BRIEF

published on 08/25/2025 at 07:05, 6 months 22 days ago

OSE Immunotherapeutics: New Governance and Strategic Objectives

Shareholders Biotechnology Governance Strategy Tedopi And Lusvertikimab
PRESS RELEASE

published on 08/25/2025 at 07:00, 6 months 22 days ago

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
OSE Immunotherapeutics announces proposed governance evolution and reaffirms strategic priorities ahead of Annual General Meeting. Company focuses on Tedopi® and Lusvertikimab to unlock full potential

Strategic Priorities Governance Evolution OSE Immunotherapeutics Lusvertikimab Tedopi
BRIEF

published on 08/20/2025 at 18:05, 6 months 27 days ago

OSE Immunotherapeutics Appoints Thomas Gidoin as CFO

Chief Financial Officer Strategic Planning Biotech Financing OSE Immunotherapeutics Thomas Gidoin
PRESS RELEASE

published on 08/20/2025 at 18:00, 6 months 27 days ago

OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
OSE Immunotherapeutics appoints Thomas Gidoin as Chief Financial Officer, bringing deep expertise in capital markets and financial strategy to the company. Gidoin succeeds Anne-Laure Autret-Cornet

Chief Financial Officer Capital Markets Financial Strategy OSE Immunotherapeutics Thomas Gidoin
BRIEF

published on 07/02/2025 at 08:05, 8 months 14 days ago

OSE Immunotherapeutics Updates on Legal Proceedings

Transparency Shareholder Meeting Legal Proceedings OSE Immunotherapeutics Nantes Commercial Court
PRESS RELEASE

published on 07/02/2025 at 08:00, 8 months 14 days ago

OSE Immunotherapeutics met à jour l’information sur les procédures en cours
OSE Immunotherapeutics provides an update on ongoing legal proceedings regarding shareholders' motions, confirms plans for annual shareholders' meeting on September 30, 2025

Shareholders Biotech Annual Meeting Legal Proceedings OSE Immunotherapeutics
BRIEF

published on 06/20/2025 at 19:35, 8 months 26 days ago

OSE Immunotherapeutics secures its General Meeting

Shareholders Transparency General Assembly Legal Proceedings OSE Immunotherapeutics
PRESS RELEASE

published on 06/20/2025 at 19:30, 8 months 26 days ago

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
OSE Immunotherapeutics reaffirms commitment to transparent and serene General Meeting in compliance with market rules, providing 'Questions and Answers' document for shareholders

Shareholders Transparency General Meeting OSE Immunotherapeutics Market Rules
BRIEF

published on 06/19/2025 at 15:58, 8 months 27 days ago

Strategic change within OSE Immunotherapeutics

Board Of Directors General Meeting Crossing Thresholds OSE Immunotherapeutics Shareholders' Agreement

Published on 03/16/2026 at 22:45, 7 hours 31 minutes ago

Copper Road Announces Closing of Financing
Published on 03/16/2026 at 22:30, 7 hours 46 minutes ago

Core Silver Intersects High-Grade Copper-Molybdenum Veins up to 7.31% Cu & 1.01% Mo Confirming Large Porphyry System at Laverdiere
Published on 03/16/2026 at 22:00, 8 hours 16 minutes ago

Viemed Healthcare to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19
Published on 03/16/2026 at 21:30, 8 hours 46 minutes ago

Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity
Published on 03/16/2026 at 21:00, 9 hours 16 minutes ago

Amdocs Brings AI-Accelerated Application Modernization to Enterprises with NVIDIA

View all ACCESSWIRE

Published on 03/17/2026 at 03:40, 2 hours 35 minutes ago

SANY and OCHA Sign Partnership Agreement at HNPW 2026
Published on 03/17/2026 at 02:10, 4 hours 5 minutes ago

Clawchain.ai Launches on Chromia to Support the Next Generation of AI Agent Systems
Published on 03/17/2026 at 00:00, 6 hours 15 minutes ago

Cango Inc. Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results
Published on 03/16/2026 at 23:07, 7 hours 8 minutes ago

KION brings physical AI into live warehouse operations at GTC 2026 in San José, California
Published on 03/16/2026 at 22:35, 7 hours 40 minutes ago

Nscale and Microsoft Announce Collaboration with NVIDIA and Caterpillar to Deliver 1.35GW of NVIDIA Vera Rubin NVL72 GPUs at Flagship AI Factory Campus in West Virginia

View all EQS

Published on 03/16/2026 at 18:00, 12 hours 16 minutes ago

Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 12 hours 18 minutes ago

Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 12 hours 19 minutes ago

Reporting on share buyback transactions carried out between March 9 and March 13, 2026
Published on 03/16/2026 at 17:45, 12 hours 31 minutes ago

Weekly share buyback
Published on 03/16/2026 at 17:35, 12 hours 41 minutes ago

Disclosure of transactions in own shares from March 9 to March 13, 2026

View all LES ECHOS COMFI WIRE

News